Is the Medical Developments investment thesis broken? (ASX: MVP)

MVP has announced profit of $500,000 plus or minus $360,000, and I just can’t stand the unnecessary ambiguity.

Medical Developments International receives FDA approval for Space Chamber asthma spacers (ASX: MVP)

It has been announced this morning that Medical Developments International has received FDA approval for its Space Chamber asthma spacers. Since I bought shares, the company has moved forward with a number of its initiatives (selling asthma devices into the USA is just one of them). Importantly, the application for marketing approval of Penthrox in […]

Update on Medical Developments: negative profit guidance, as expected (ASX:MVP)

Medical Developments (MVP) recently updated the market as to its operations and expected profits for FY13. As expected, net profit is expected to be down on 2012, by up to 15%. The market immediately reacted to this, and what followed was two days of savage selling… to a low of $1.06. Since then, the share […]

An Introduction to Medical Developments International (ASX:MVP)

Share Price: $1.40 Market Capitalisation: Approximately $81 Million Medical Developments International (ASX:MVP) is a company with a variety of business segments. Their main two product lines are Penthrox® an inhaled analgesic known colloquially as the “green whistle” and a range of asthma equipment, such as face masks and spacers. In addition to this, they also sell […]